Evaluate the safety of linaclotide in IBS-C patients in China

Trial Identifier: D5630R00001
Sponsor: AstraZeneca
NCTID:: NCT04462900
Start Date: September 2020
Primary Completion Date: February 2023
Study Completion Date: February 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China
China Chongqing, China
China Qingdao, China
China Shanghai, China
China Shenzhen, China
China Suzhou, China
China Wenzhou, China
China Wulumuqi, China
China Xiamen, China
China, China Baotou, China, China, 14030
China, China Beijing, China, China, 610072
China, China Beijing, China, China, 100730
China, China Binzhou, China, China, 256603
China, China Chengdu, China, China, 610014
China, China Guangzhou, China, China, 510000
China, China Guangzhou, China, China, 510655
China, China Guangzhou, China, China, 518110
China, China Jinan, China, China, 250012
China, China Leshan, China, China, 614000
China, China Nanchang, China, China, 330006
China, China Nanjing, China, China, 210008
China, China Nanjing, China, China, 210029
China, China Shanghai, China, China, 200025
China, China Shanghai, China, China, 200433
China, China Shenyang, China, China, 110001
China, China Shenzhen, China, China, 518035
China, China Taiyuan, China, China, 030012
China, China Tianjin, China, China, 300052
China, China Wuhan, China, China, 430022
China, China Xian, China, China, 710000
China, China Zhengzhou, China, China, 450003